Hydroxychloroquine, along with other illnesses, such as lupus and arthritis, has long been used in traditional malaria. It is used in fever and inflammation, and the expectation is that the virus COVID-19 will also be cured with it.
The malaria medicine hydroxychloroquine has become advertised by others, like President Trump, as essentially a miraculous cure for COVID-19.
However, new clinical evidence indicates that patients with coronavirus do not get better with simple medication.
Researchers in Iran, evaluated six studies that suggested that the drug could marginally reduce recovery time, including small studies in France as well as in China. All six of the studies confronted standard hydroxychloroquine with standard treatment, which may include, where appropriate, testing, liquid, oxygen, and other care.
In all studies, scientists have reported that there have been no statistically significant differences in results for patients, who have been given hydroxychloroquine or those who do not.
Significant numbers of people taking the medication demonstrated clearer lungs in comparison with those on standard medication. And after taking the vaccine, the virus’s genetic information was also observable in significantly fewer individuals than others who didn’t take drugs.
But there have also been more minor adverse effects, such as blisters and headaches, in the group consuming hydroxychloroquine.
The researcher argued, that there have been few enough patients in the research to give a firm outcome, whether the medication works as expected or not.
Researchers also found there were far more fatalities among men who took hydroxychloroquine relative to those not taking these drugs.
A higher mortality rate was not linked to hydroxychloroquine. The use of hydroxychloroquine interfaces with the heart and can result in heart failure.
President Trump has utilized hydroxychloroquine as a safety precaution. However, amid early trials that raised expectations, a larger trial later showed that treatment isn’t successful.